Korea IND Filing Moves Alteogen's Eylea Biosimilar Forward

 
• By Jung Won Shin

South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.

Eye
Alteogen Files Korea IND For Eylea Biosimilar • Source: Shutterstock

Alteogen Inc. has filed an IND to begin clinical trials with its biosimilar version of Eylea (aflibercept) in South Korea, moving forward with its plan to become a global first mover for the biosimilar product both at home and abroad.

The planned randomized, double-blind Phase I trial will evaluate the safety, efficacy and pharmacokinetics of ALT-L9, its biosimilar of

More from South Korea

More from Focus On Asia